That may be the RAP position, but the market for this type of service has not really been tested yet. In the current environment, where they may get lots of tests and start a promising revenue stream, with many demands on health dollars, they may settle for less. That's not necessarily a bad thing.
Ann: ResApp Builds European Market Presence, page-83
-
- There are more pages in this discussion • 181 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)